RAZADYNE for Alzheimer's

Razadyne_cover.PNG
Razadyne_cover.PNG

RAZADYNE for Alzheimer's

0.00

FDA approved RAZADYNE immediate release tablets in 2001 based on evidence from four randomized trials with similar results. The three longest trials included 1,686 people with mild-to-moderate Alzheimer’s Disease (average MMSE of 19) who were an average of 76 years old; about two thirds were women. Researchers randomly assigned participants to take either RAZADYNE immediate release tablets or a placebo (inactive sugar pill) for 5 to 6 months. Get the DrugFactsBox to see what happened. 

Read about Consumer Reports' take on RAZADYNE here.

Add To Cart